Molecular Imaging in Drug R&D and Medical Practice: Technologies, Applications, Markets

By Ken Rubenstein, PhD

Chapter 1
INTRODUCTION
1.1. Biomarker Definitions
1.2. Organization of the Report

Chapter 2
IN VIVO MOLECULAR IMAGING TECHNOLOGIES
2.1. Historical Introduction
2.2. Imaging Technologies
Computed Tomography
Positron Emission Tomography
Single Photon Emission Computed Tomography
Magnetic Resonance Imaging
Ultrasound
Optical Imaging
2.3. Combination Technologies
2.4. Molecular and Functional Imaging

Chapter 3
IMAGING BIOMARKERS IN DRUG DEVELOPMENT
3.1. Preclinical Development
3.2. Clinical Development
3.3. Therapeutic Areas
Cancer
      Cell Proliferation or Metabolism
      Apoptosis
      Angiogenesis
      Hypoxia
      Other Parameters
Neurological Disease
      Alzheimer's Disease
      Parkinson's Disease
Cardiovascular Disease
Inflammatory and Autoimmune Disease

Chapter 4
MOLECULAR IMAGING IN DIAGNOSTICS
4.1. Cancer
4.2. Cardiovascular Disease
4.3. Neurological Disease

Chapter 5
CONSORTIA, GOVERNMENT, AND REGULATORY CONSIDERATIONS
5.1. Consortia and Professional Society Involvement
Biomarkers Consortium
Oncology Biomarker Qualification Initiative (OBQI)
Uniform Protocols for Imaging in Clinical Trials (UPICT)
Imaging Response Assessment Teams (IRATs)
5.2. Government Involvement
NIH Molecular Libraries and Imaging Roadmap
Network for Translational Research: Optical Imaging (NTROI)
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Institute for Molecular Technology (IMT)
National Oncologic PET Registry (NOPR)
5.3. FDA Regulatory Guidance
5.4. National Academy of Sciences Report

Chapter 6
MARKET CONSIDERATIONS
6.1. The Molecular Imaging Market Ecology
Radiopharmaceuticals
Instruments
Software
6.2. Market Analysis and Dynamics
Facilitation of Imaging Agent Development
PET Versus SPECT
6.3. Drug Discovery and Development Market
Large Company Business Models
The Convergence of In Vitro and In Vivo Diagnostics
6.4. Deals in Molecular Imaging
Categorization of Deals
Market Size and Growth Projects

Chapter 7
EXPERT INTERVIEWS
Sudeep Chandra, PhD, General Manager of Molecular Imaging, Philips Healthcare
Terry A. Colip, Managing Partner and CFO, Cell>Point, LLC
J. James Frost, MD, PhD, Professor of Radiology and Psychiatry, Yale University, School of Medicine
Antony Gee, PhD, Director of PET and Radiotracer Development, GlaxoSmithKline
Franz Hefti, PhD, Chief Scientific Officer, Avid Radiopharmaceuticals
Patrick McConville, PhD, Director of Imaging, MIR Preclinical Services
Jean-Luc Vanderheyden, PhD, Global Molecular Imaging Leader, GE Healthcare

APPENDIX
INSIGHT PHARMA REPORTS MOLECULAR IMAGING SURVEY-OCTOBER 2007
Observations from the Survey

References
Company Index with Web Addresses